You are here

Session on Cardio-nephrology: cardiotoxicities of cancer in childhood cancer survivors

By Steven E. Lipshultz, recorded at TAO (Transatlantic Oncology meeting), Nov 20-21, 2014, Paris

5 - Steven Lipschultz ANG

Successful treatment of childhood cancer used to be defined by 5-year event-free survival, but the tremendous advances in cancer treatment enable oncologists to focus on toxicities and late effects. Steven E. Lipshultz discusses the new paradigm that the successful treatment of cancer is determined by the balance between oncologic efficacy and toxicity/late effects as measured by quality of life for the patients and their families over a lifespan. This is important as the global risk of premature symptomatic cardiovascular disease is elevated in childhood cancer survivors and long-term follow-up studies have shown that cardiovascular deaths continue to go up at an exponential pace even decades after exposure to cardiotoxic therapy.The five stages in the course of pediatric ventricular dysfunction are: presence of risk factors, cardiomyocyte injury or impairment, maladaptive changes, cardiomyopathy, heart failure or clinically significant condition and rhythm abnormalities. Steven E. Lipshultz reviews preventive strategies and treatment options, stressing the need for tailored follow-ups and therapies.

 

Steven E. Lipshultz, Wayne University, Detroit, USA

Search this site

Stay up-to-date with our monthly e-alert

If you want to regularly receive information on what is happening in Quality of Life in Oncology research sign up to our e-alert.

Subscribe »

QOL (Quality of Life) newsletter e-alert

NEW! Free access to the digital version of a new publication in Cancer Supportive Care


Cancer cachexia: mechanisms and progress in treatment

Authors: Egidio Del Fabbro, Kenneth Fearon, Florian Strasser

This book was supported by an educational grant from Helsinn Healthcare SA.

Featured videos

Quality of Life promotional video

Made possible by an educational grant from Helsinn

Helsinn does not have any influence on the content and all items are subject to independent peer and editorial review

Society Partners

European Cancer Organisation Logo

Share